Prognia
All Conditions
CardiologyICD-10: I10

Hypertension: Current Treatment Guidelines & Management

Affects 1.28 billion adults aged 30–79 worldwide; the leading modifiable risk factor for cardiovascular disease globally.

NICE 2023ESC 2018

What is Hypertension?

Hypertension is defined as persistently elevated blood pressure ≥140/90 mmHg (NICE/ESC) or ≥130/80 mmHg (AHA/ACC 2017). It is classified by grade: Grade 1 (140–159/90–99 mmHg), Grade 2 (160–179/100–109 mmHg), Grade 3 (≥180/110 mmHg). Hypertension is the most prevalent modifiable cardiovascular risk factor, contributing to 50% of all heart disease and 60% of all strokes globally.

Pathophysiology

Most hypertension (>90%) is primary/essential, arising from complex interactions between genetic predisposition, dietary factors (sodium excess, potassium deficiency), adiposity, physical inactivity, and autonomic/RAAS dysregulation. Chronic elevation causes vascular remodelling, arterial stiffening, left ventricular hypertrophy, and accelerated atherosclerosis. Secondary causes (renal artery stenosis, primary aldosteronism, phaeochromocytoma, coarctation) account for 5–10% and should be excluded in young patients, resistant hypertension, or atypical features.

Clinical Features & Symptoms

  • Usually asymptomatic ("silent killer") — majority have no symptoms
  • Headache (typically occipital, morning)
  • Dizziness and visual disturbance
  • Epistaxis (acute severe hypertension)
  • Hypertensive retinopathy (papilloedema in malignant HT)
  • Symptoms of end-organ damage: dyspnoea (HF), chest pain (CAD), neurological deficits (stroke)

Diagnosis

NICE 2023 recommends ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM) to confirm hypertension after a clinic BP ≥140/90 mmHg. ABPM daytime average ≥135/85 mmHg or 24-hour average ≥130/80 mmHg confirms hypertension. Clinic BP may be used if ABPM is declined or not tolerated. Investigate for end-organ damage: ECG, urine ACR, eGFR, lipids, fasting glucose.

Current Treatment Guidelines

Lifestyle modification

Class I, Level A

Low-sodium diet (<6 g/day), DASH diet, ≥150 min/week aerobic exercise, weight loss, alcohol reduction (<14 units/week), smoking cessation. Reduces systolic BP by 5–20 mmHg.

Step 1: ACE inhibitor or ARB

Class I, Level A

ACE inhibitor (e.g. ramipril) or ARB (e.g. losartan) for most patients, especially with diabetes, CKD, or proteinuria. ARB preferred if ACE inhibitor-associated cough. Never combine ACE-I and ARB.

Step 2: Add calcium channel blocker

Class I, Level A

Amlodipine or equivalent dihydropyridine CCB as add-on therapy. Combination with ACE-I/ARB is well-tolerated and synergistic. Rate-limiting CCBs (diltiazem) for patients intolerant of beta-blockers.

Step 3: Add thiazide-like diuretic

Class I, Level A

Indapamide (preferred) or chlortalidone. Add as third agent if BP not controlled on dual therapy. Monitor electrolytes and glucose.

Resistant hypertension (Step 4)

Class IIa, Level B

Add spironolactone 25–50 mg if no contraindications (PATHWAY-2 trial). Alternatively, add alpha-blocker or beta-blocker. Refer for secondary hypertension investigation.

Single-pill combination (SPC)

Class I, Level A

NICE 2023 and ESC 2018 recommend initiating with SPC as first-line to improve adherence. Starting with two drugs simultaneously (ACE-I/ARB + CCB) achieves BP targets faster with better adherence than monotherapy.

Monitoring & Treatment Targets

BP target: <140/90 mmHg for most adults (NICE); <130/80 mmHg preferred for adults <80 with high CV risk (AHA). In patients ≥80 years: <150/90 mmHg. Reassess BP at 1 month after initiation, then every 3–6 months. Annual: eGFR, electrolytes, uACR.

Key Clinical Trials

PATHWAY-2Lancet, 2015

Spironolactone most effective add-on for resistant hypertension, reducing systolic BP by 8.7 mmHg more than placebo (p<0.0001)

SPRINTNEJM, 2015

Intensive BP target (<120 mmHg systolic) reduced MACE by 25% and all-cause mortality by 27% vs standard target (<140 mmHg) in non-diabetic high-risk adults

Clinical Guidelines

NICE 2023

NICE Hypertension in Adults: Diagnosis and Management 2023 Update

ESC 2018

ESC/ESH Guidelines for the Management of Arterial Hypertension 2018

External Resources

NICE Hypertension Guideline NG136ESC/ESH Hypertension Guidelines 2018WHO Hypertension Fact Sheet

AI Clinical Analysis

Requires free account

Ask Prognia AI about Hypertension — get evidence-graded answers from PubMed, the linked guidelines, and real clinical cases simultaneously.

Ask about HypertensionCreate Free Account

Frequently Asked Questions

What blood pressure is considered hypertension?

NICE (UK) and ESC (Europe) define hypertension as a clinic blood pressure ≥140/90 mmHg, confirmed by ABPM (daytime average ≥135/85 mmHg). The AHA/ACC 2017 guidelines use a lower threshold of ≥130/80 mmHg. Most treatment initiation targets are based on the NICE/ESC threshold, though intensive targets (<130/80) are recommended for high-risk patients.

What is the first-line drug for hypertension?

NICE 2023 and ESC 2018 both recommend starting with an ACE inhibitor (e.g. ramipril) or ARB (e.g. losartan) as first-line for most patients, particularly those with diabetes, CKD, or previous stroke. A single-pill combination (ACE-I/ARB + CCB or thiazide) is preferred to improve adherence and achieve faster BP control.

What is resistant hypertension?

Resistant hypertension is defined as blood pressure remaining above target despite adherence to ≥3 antihypertensive medications at optimal doses (including a diuretic). Before diagnosing true resistance, exclude pseudoresistance (white coat effect, poor adherence, incorrect measurement technique). The PATHWAY-2 trial established spironolactone as the most effective fourth-line agent for resistant hypertension.

Medical disclaimer: This content is intended for qualified healthcare professionals and does not constitute medical advice. Always apply clinical judgment and refer to current local guidelines and institutional protocols.